Novartis says swine flu vaccine boosts profit

Jan 26, 2010

Swiss pharmaceutical group Novartis posted on Tuesday an 8.0-percent jump in core annual net profit for 2009, saying that business had been boosted by sales of swine flu vaccine.

The Basel-based company also announced that Daniel Vasella would hand over the chief executive's post to Joe Jimenez, the head of the pharmaceuticals division, a job Vasella had combined with the chairmanship for 11 years.

Vasella, reporting core net profit for last year of 10.3 billion dollars (7.3 billion euros), said: " delivered an excellent performance in 2009 driven by strong underlying growth across our entire healthcare portfolio."

The Swiss giant's , launched alongside rival vaccine makers last year in response to the pandemic alert and state-led campaigns, helped overall net sales grow by seven percent to 44.3 billion, the company said.

"Vaccines and Diagnostics achieved exceptionally high sales by rapidly developing and delivering influenza A (H1N1) vaccines to address the public health threat," the company said.

Novartis said it expected to "maintain momentum" in 2010 with a strong array of newly launched drugs, and helped on by the 40-billion-dollar acquisition of dominant eye care group Alcon from Nestle this month.

"Over the past 12 months, we sustained our lead in approvals for new products, achieving more than 30 major new product approvals in the US, Europe and Japan," Vasella said.

"The planned acquisition of Alcon will propel Novartis to the global leadership position in eye-care and create a new growth platform," he added.

The core annual net profit of 10.3 billion dollars compared with profit of 9.5 billion dollars in 2008.

Excluding exceptional items, full-year profit reached 8.4 billion francs, an increase of four percent over the equivalent figure the previous year.

Analysts polled by financial agency AWP had forecast a net profit of 8.6 billion dollars.

Core operating income was up 11 percent to 11.4 billion dollars, Novartis said.

Operating income in the vaccines division more than doubled to 719 million dollars, an increase of 133 percent over 2008, while sales grew 38 percent.

Operating income in the group's core business and biggest earner, pharmaceuticals, grew by 10 percent to 9.07 billion dollars in 2009 on sales growth of eight percent.

Novartis said that Vasella, who became chief executive 14 years ago, would relinquish the post to Jimenez on February 1, under a transition process it began in 2008.

Vasella will continue as chairman of the group, focusing on strategy, it added.

Explore further: World's first wearable blue LED light therapy device to treat skin disease psoriasis vulgaris

add to favorites email to friend print save as pdf

Related Stories

Taiwan's HTC says profit down 30 percent

Apr 06, 2009

Taiwan's smartphone maker HTC Corp posted a year-on-year 30 percent fall in first quarter net profit as the global economic meltdown hit sales, the company said Monday.

HP profits lower, to cut nearly 6,400 workers

May 19, 2009

US computer giant Hewlett-Packard reported a 17-percent fall in quarterly net profit on Tuesday and said it plans to cut two percent of its workforce, or nearly 6,400 workers, over the next year.

SKorea's Hynix finally swings to profit

Oct 23, 2009

South Korea's Hynix Semiconductor, the world's second largest memory chip maker, Friday announced a profit for the third quarter after seven straight quarters of losses.

Washington Post stems tide of red ink

Jul 31, 2009

The Washington Post Co. reversed its slide and posted a quarterly profit on Friday despite a steep decline in advertising revenue at its flagship newspaper.

Taiwan's HTC earnings edge down in Q2

Jul 06, 2009

HTC Corp, Taiwan's leading smartphone maker, said Monday its net profit in the second quarter was down almost two percent from a year earlier.

Recommended for you

Motion capture examines dance techniques

Sep 29, 2014

WAAPA dance students are set to take part in a world-first biomechanical study that tracks their training, technique and injuries as they develop as professional performers.

User comments : 0